Sigma 1 Agonist Presses Forward After Positive Results in Small Alzheimer ’s Trial

SAN DIEGO — A novel Alzheimer’s disease drug candidate appeared to stabilize cognition and function over 57 weeks in a small, early-phase, open-label trial.

Source: Caring for the Ages - February 28, 2017 Category: Health Management Authors: Michele G. Sullivan Source Type: news